375 related articles for article (PubMed ID: 8810132)
1. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
3. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
5. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
7. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma].
Fernández Megía MJ; Alós Almiñana M; Esquer Borrás J
Farm Hosp; 2004; 28(6):433-9. PubMed ID: 15628946
[TBL] [Abstract][Full Text] [Related]
9. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
11. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
12. Late-onset delayed excretion of methotrexate.
Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
[TBL] [Abstract][Full Text] [Related]
13. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
Kawakami M; Omori H; Yamagami T; Soma T
Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
[TBL] [Abstract][Full Text] [Related]
14. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
15. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
16. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
17. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate: pharmacokinetics in children and young adults.
Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
20. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
